Given the existence of targeted agents (PARP inhibitors) that are approved for BRCA1/2 mutant patients in several cancers, including breast, ovarian, prostate, and pancreatic cancer, it would be interesting to delineate these genes’ role in USCs. The gene discussed is BRCA1; the disease is pancreatic neoplasm.